2025
How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D Report
Zisook S, Johnson G, Planeta B, Mohamed S. How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D Report. Journal Of Clinical Psychopharmacology 2025, 45: 421-431. PMID: 40742171, DOI: 10.1097/jcp.0000000000002051.Peer-Reviewed Original ResearchConceptsPositive mental healthTreatment-resistant depressionNext-step treatmentPositive mental health scoresAssociated with greater severityTreatment predictorsChronicity of depressionLikelihood of remissionSelf-rating questionnaireAssociated with high remissionComorbid PTSDDepressive disorderDepression trialsSuicidal ideationGreater severityWeeks of treatmentDepressionLow quality of lifeMental healthMDDSwitching treatmentTreatment outcomesPredictors of outcomeBupropionHigher remission
2024
Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment
Choi H, Kim J, Yang H, Kim J, Cortese S, Smith L, Koyanagi A, Dragioti E, Radua J, Fusar-Poli P, Shin J, Cheon K, Solmi M. Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment. Molecular Autism 2024, 15: 7. PMID: 38263251, PMCID: PMC10807060, DOI: 10.1186/s13229-024-00585-6.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderNon-pharmacological interventionsRisperidone monotherapyParent trainingPharmacological monotherapySpectrum disorderTreatment of irritabilityRandomized Controlled TrialsAdjuvant therapyRisperidoneReplicate findingsEfficacy of interventionsEffect sizePooled effect sizeHedges’ g.AripiprazoleEligible interventionsMeta-analysisPharmacological interventionsAutismRandom-effects meta-analysisCertainty of evidenceRisk of biasDisordersMeta-analyses
2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2022
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchConceptsAntipsychotic drugsTourette syndromeComorbid attention-deficit hyperactivity disorderSecond-generation antipsychotic drugsModerate certainty of evidenceAttention-deficit hyperactivity disorderCertainty of evidenceNetwork Meta-AnalysisPharmacological interventionsSeverity of tic symptomsObsessive-compulsive disorderIndividual medicationsRandomised controlled trialsFirst-generationDiscontinuation due to adverse eventsSecond-generationAntipsychotic medicationControlled TrialsModerate certaintyHyperactivity disorderMeta-analysisTic symptomsChoice of medicationMedication categoriesTouretteThe impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials
Croatto G, Vancampfort D, Miola A, Olivola M, Fiedorowicz J, Firth J, Alexinschi O, Gaina M, Makkai V, Soares F, Cavaliere L, Vianello G, Stubbs B, Fusar-Poli P, Carvalho A, Vieta E, Cortese S, Shin J, Correll C, Solmi M. The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials. Molecular Psychiatry 2022, 28: 369-390. PMID: 36138129, PMCID: PMC9493151, DOI: 10.1038/s41380-022-01770-w.Peer-Reviewed Original ResearchConceptsMood disordersPhysical health outcomesBipolar depressionSerotonin-noradrenaline reuptake inhibitorsModerate ESSmall ESPhysical health-related quality of lifeImprove physical healthReuptake inhibitorsBipolar disorderComorbid medical diseasesPsychological interventionsUmbrella reviewHealth outcomesMeta-analysesMoodNon-pharmacological interventionsHigher discontinuation rateMeta-analyses of randomised controlled trialsDepressionHealth-related quality of lifePhysical healthAssociated with negative effectsControlled TrialsDisorders
2020
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
Digital medicine systems: an evergreening strategy or an advance in medication management?
Egilman AC, Ross JS. Digital medicine systems: an evergreening strategy or an advance in medication management? BMJ Evidence-Based Medicine 2019, 24: 203-204. PMID: 31754072, DOI: 10.1136/bmjebm-2019-111265.Commentaries, Editorials and LettersGeneral Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2017
Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder
Feeley RJ, Arnaout B, Yoon G. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 729-730. PMID: 29028689, DOI: 10.1097/jcp.0000000000000794.Peer-Reviewed Original ResearchEffect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
2016
Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male
Schindler EA, Guo XM, Schrag M, Ghoshal S, Schilsky ML, Beslow LA. Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male. Neuropediatrics 2016, 47: 346-347. PMID: 27490186, DOI: 10.1055/s-0036-1586225.Peer-Reviewed Original ResearchAdenosine TriphosphatasesAdolescentAggressionAntidepressive AgentsAntipsychotic AgentsAripiprazoleBrainCation Transport ProteinsCitalopramCopper-transporting ATPasesDepressionDiplopiaDysarthriaEsophageal and Gastric VaricesHepatolenticular DegenerationHumansHypertension, PortalImpulsive BehaviorLiver CirrhosisMagnetic Resonance ImagingMaleMutationSuicidal IdeationCharacteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideationPharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis
Fung L, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A, Veenstra-Vanderweele J, Hardan A. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. 2016, 137: s124-s135. PMID: 26908468, DOI: 10.1542/peds.2015-2851k.Peer-Reviewed Original ResearchConceptsPharmacologic treatmentSide effectsPrimary study outcome measureAutism spectrum disorderPlacebo-controlled RCTsExtrapyramidal side effectsStudy outcome measuresEnd of treatmentRisk of biasParallel group designYouth ages 2Potential side effectsPublic health issueDetails of interventionsEffect sizeMedication groupAdverse reactionsSevere irritabilityOutcome measuresSignificant efficacyLarge effect sizesMeta-analysisSystematic reviewStudy participantsWeight gain
2015
Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
Wang G, Zhang Y, Zhang S, Chen H, Xu Z, Schottenfeld RS, Hao W, Chawarski MC. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. Journal Of Substance Use And Addiction Treatment 2015, 62: 84-88. PMID: 26733277, PMCID: PMC4724444, DOI: 10.1016/j.jsat.2015.11.009.Peer-Reviewed Original ResearchConceptsRisperidone-treated patientsSimpson-Angus ScaleVisual analog scalePsychotic symptomsRisperidone groupSelf-reported adverse effectsClinical Global Impressions-SeverityKaplan-Meier survival analysisAdverse effectsAripiprazole-treated patientsEfficacy of aripiprazoleMethamphetamine-Associated PsychosisExtra-pyramidal symptomsInpatient hospital stayTreatment of methamphetamineNegative Syndrome ScaleGreater methamphetamineHospital stayAripiprazole groupEntire studyAngus ScaleAnalog scaleAcute methamphetamineChinese patientsIllness ScaleAripiprazole-Induced Transient Morning Pseudoneutropenia in an 11-Year-Old Male
Pinnaka S, Roberto AJ, Giordano A, Siller P, Lapidus K. Aripiprazole-Induced Transient Morning Pseudoneutropenia in an 11-Year-Old Male. Journal Of Child And Adolescent Psychopharmacology 2015, 26: 858-859. PMID: 26397725, DOI: 10.1089/cap.2015.0128.Peer-Reviewed Original ResearchThe VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original Research
2013
Aspirin as an Adjunctive Treatment for Childhood Onset Schizophrenia
Webb JR, Stubbe DE, Poncin YB. Aspirin as an Adjunctive Treatment for Childhood Onset Schizophrenia. Journal Of Child And Adolescent Psychopharmacology 2013, 23: 585-586. PMID: 24138014, DOI: 10.1089/cap.2013.0033.Peer-Reviewed Original ResearchAripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
Liu C, Chien Y, Hsieh M, Hwang T, Hwu H, Liu C. Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis. Journal Of Clinical Psychopharmacology 2013, 33: 18-23. PMID: 23277261, DOI: 10.1097/jcp.0b013e31827cb017.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisUltra-high riskFirst-episode psychosis patientsDrug-naiveUltra-high risk stateUltra-high-risk patientsLow-dose aripiprazoleNegative symptom scoresPositive symptom scoresFlexible dosing strategyState of psychosisTreatment responseAntipsychotic therapyDrug-naive populationSevere psychopathologyUHR patientsFirst-episodeAripiprazoleAdverse eventsSymptom scoresPsychosisRisk stateConcomitant medicationsTarget doseClinical improvement
2012
Hypomania Associated With Adjunctive Aripiprazole in an Elder Female With Recurrent Major Depressive Disorder
Lin H, Lin C, Liu C. Hypomania Associated With Adjunctive Aripiprazole in an Elder Female With Recurrent Major Depressive Disorder. Journal Of Clinical Psychopharmacology 2012, 32: 836-837. PMID: 23131891, DOI: 10.1097/jcp.0b013e318272d2b7.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply